Many teams fail with AI because they try to force-fit the technology onto problems. The winning approach is to first identify a critical business challenge, define success metrics, and only then determine if AI is the appropriate solution. This avoids applying a solution in search of a problem and addresses crucial change management.
Large pharma companies increasingly rely on smaller biotechs for early-stage, high-risk innovation. Startups operate with higher risk tolerance and faster decision-making. Once a drug shows promise, the larger company, with its vast resources and expertise in running large-scale trials, steps in to license or acquire it for scaling.
To successfully guide clients or internal teams, innovators must stay close to their current reality. Being one or two steps ahead provides a clear, achievable path forward. Being five steps ahead creates a disconnect, as the team cannot grasp the vision or feel the proposed changes are relevant to their immediate problems.
AI-powered chatbots do more than just engage patients in clinical trials. By analyzing the content and sentiment of a patient's queries, these systems can identify individuals at high risk of dropping out. This allows a human coordinator to intervene proactively, address concerns, and improve overall patient retention.
The highest-value application of AI in clinical development is in the design phase. By simulating trial outcomes with historical data and virtual patient cohorts, companies can identify and resolve potential bottlenecks, like flawed protocols or recruitment issues, before committing massive resources. This
Digital twins and virtual trials are not currently used to replace human clinical trials. Instead, they serve as powerful simulation tools to 'test drive' protocols with virtual patient data. This helps create synthetic control arms, anticipate challenges, and optimize trial designs before launching a costly real-world study.